Drug Quality Co-regulation Supervision Strategy Considering Collusion Behavior With New Media Participation
Authors:
Open Access
- 29 April 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 10, 858705
Abstract
The efficiency and level of drug quality supervision are highly related to the distorted or true reporting of new media, and the collusion or non-collusion of third-party testing agencies. Therefore, based on the co-regulation information platform, considering the strategic choices of local government, drug enterprises, third-party testing agencies and new media, this article constructs a four-party evolutionary game model of co-regulation supervision. The stable equilibrium points of each participant's strategic choices are solved. The stability of the strategic combination is analyzed by Lyapunov's first method, and Matlab 2020b is used for simulation analysis to verify the influence of each decision variable on different players' strategic choices. The results show that, firstly, new media's true reporting can make up for the lack of supervision of drug enterprises by local government, and the greater the impact of new media reporting, the more active drug enterprises will be to produce high-quality drugs. Secondly, non-collusion of third-party testing agencies can improve the self-discipline ability of drug enterprises, encourage new media to report truthfully, and play the role of co-regulation supervision. Furthermore, the greater the probability of new media's true reporting, the more local government tend to be stricter, and the probability of strict supervision is positively related to the central government's accountability. Finally, increasing penalty for producing low-quality drugs and collusion will help standardize the behavior of drug enterprises and third-party testing agencies. This article enriches and expands the theoretical basis of the drug quality co-regulation supervision and proposes corresponding countermeasures and suggestions.Keywords
Funding Information
- National Social Science Fund of China (No.20BGL272, No.21ZDA024)
This publication has 19 references indexed in Scilit:
- Quality Decision-Making Practices in Pharmaceutical Companies and Regulatory Authorities: Current and Proposed Approaches to Its DocumentationTherapeutic Innovation & Regulatory Science, 2020
- What drives public agencies to participate in open government data initiatives? an innovation resource perspectiveInformation & Management, 2020
- Countries test tactics in ‘war’ against COVID-19Science, 2020
- 2019-nCoV epidemic: address mental health care to empower societyThe Lancet, 2020
- How to govern the digital transformation of health servicesEuropean Journal of Public Health, 2019
- Emergency management in the changing world of social media: Framing the research agenda with the stakeholders through engaged scholarshipInternational Journal of Information Management, 2019
- Social Media and the Formation of Organizational ReputationAcademy of Management Review, 2019
- The Effect of Unannounced Inspection on Prevention of Drug FraudJournal of Systems Science and Systems Engineering, 2018
- A systematic assessment of key design and performance characteristics of drug exposure registries requested by the U.S. Food and Drug AdministrationPharmacoepidemiology and Drug Safety, 2018
- Corporate Sociopolitical Involvement: A Reflection of Whose Preferences?Academy of Management Perspectives, 2016